10.5061/DRYAD.4V23B
Mbulawa, Zizipho Z.A.
van Schalkwyk, Cari
Stellenbosch University
Hu, Nai-Chung
University of Cape Town
Meiring, Tracy L.
University of Cape Town
Barnabas, Shaun
University of Cape Town
Dabee, Smritee
University of Cape Town
Jaspan, Heather
University of Cape Town
University of Washington
Kriek, Jean-MAri
University of Cape Town
Jaumdally, Shameem Z.
University of Cape Town
Muller, Etienne
Bekker, Linda-Gail
University of Cape Town
Lewis, David A.
University of Sydney
Dietrich, Janan
University of the Witwatersrand
Gray, Glenda
University of the Witwatersrand
South African Medical Research Council
Passmore, Jo-Ann S.
University of Cape Town
National Health Laboratory Service
Williamson, Anna-Lise
University of Cape Town
National Health Laboratory Service
Mbulawa, Zizipho Z. A.
University of Cape Town
Data from: High human papillomavirus (HPV) prevalence in South African
adolescents and young women encourages expanded HPV vaccination campaigns
Dryad
dataset
2018
sexual transmitted infection
Human papillomavirus
vaccine
2006 to 2009
Papillomaviridae
2018-12-14T00:00:00Z
2018-12-14T00:00:00Z
en
https://doi.org/10.1371/journal.pone.0190166
64616 bytes
1
CC0 1.0 Universal (CC0 1.0) Public Domain Dedication
Objectives: To investigate prevalence of cervical human papillomavirus
(HPV) genotypes to inform HPV vaccination strategy in South Africa and to
study factors associated with HPV prevalence. Methods: Sexually active,
HIV-negative women, aged 16-22 years recruited from Soweto (n=143) and
Cape Town (n=148) were tested for cervical HPV and other genital
infections. Results: Overall HPV prevalence was 66.7% (194/291) in young
women. Cape Town women were more likely to have multiple HPV infections
than the Soweto women (48.0%, 71/148 versus 35.0%, 50/143 respectively,
p=0.033) and probable HR-HPV types (34.5%, 51/148 versus 21.7%, 31/143
respectively, p=0.022). The most frequently detected HPV types were HPV-16
(11.7%), HPV-58 (10.3%), HPV-51 (8.9%), HPV-66 (8.6%), HPV-18 and HPV-81
(7.6% each). HPV types targeted by the bivalent HPV vaccine (HPV-16/18)
were detected in 18.6% (54/291) of women, while those in the quadrivalent
vaccine (HPV-6/11/16/18) were detected in 24.7% (72/291) of women; and
those in the nonavalent vaccine (HPV-6/11/16/18/31/33/45/52/58) were
detected in 38.5% (112/291) of women. In a multivariable analysis, BV
remained significantly associated with HPV infection (OR: 4.0, 95% CI:
1.4-12.6). Women were more likely to be HPV positive if they had received
treatment for STI during the past 6-months (OR: 3.4, 95% CI: 1.1-12.4) or
if they had ever been pregnant (OR: 2.3, 95% CI: 1.1-5.5). Compared to
women who reported only one sexual partner, those with increased number of
lifetime sex partners were more likely to have HPV (4-10 partners: OR:
2.9, 95% CI: 1.1-8.0). Conclusion: The high prevalence of HPV types
targeted by the nonavalent HPV vaccine encourages the introduction of this
vaccine and catch-up HPV vaccination campaigns in South Africa. The high
burden of BV and concurrent STIs also highlights the need to improve the
prevention and appropriate management of sexually-acquired and other
genital tract infections in South African youth.
DRYAD Database for South African Adolescent studyAge and sexual debut data
was generated from questionnaires. Sexual transmitted infection was
generated from the laboratory from the specimens provided by study
participantsDRYAD.zip
South Africa